FDA/CMS parallel review process makes test for efficient identification of multiple targeted therapy options available to health care professionals, patients and eligible Medicare beneficiaries sooner
Read more: FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers